Preclinical studies with ontuxizumab have shown that treatment of tumor-bearing mice resulted in small, dysfunctional vessels in the tumors and that endosialin/TEM-1 expression on neovascular pericytes was decreased due to antibody-mediated internalization [28]. Here, CD248 is linked to neoplasm.